{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"}]}],"title":"Neuropathy Peripheral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}],"title":"Peripheral Sensory Neuropathy"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"12"},{"groupId":"OG009","value":"6"},{"groupId":"OG010","value":"2"}],"units":"Participants"}],"description":"Neurotoxicity was assessed as the number of participants with the TEAE of peripheral neuropathy.","groups":[{"description":"Ixazomib 0.24 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 220 days).","id":"OG000","title":"Dose Escalation Cohort 1: Ixazomib 0.24 mg/m^2"},{"description":"Ixazomib 0.48 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 270 days).","id":"OG001","title":"Dose Escalation Cohort 2: Ixazomib 0.48 mg/m^2"},{"description":"Ixazomib 0.8 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 137 days).","id":"OG002","title":"Dose Escalation Cohort 3: Ixazomib 0.8 mg/m^2"},{"description":"Ixazomib 1.2 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 1436 days).","id":"OG003","title":"Dose Escalation Cohort 4: Ixazomib 1.2 mg/m^2"},{"description":"Ixazomib 1.68 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 456 days).","id":"OG004","title":"Dose Escalation Cohort 5: Ixazomib 1.68 mg/m^2"},{"description":"Ixazomib 2.0 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 1621 days).","id":"OG005","title":"Dose Escalation Cohort 6: Ixazomib 2.0 mg/m^2"},{"description":"Ixazomib 2.23 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 2434 days).","id":"OG006","title":"Dose Escalation Cohort 7: Ixazomib 2.23 mg/m^2"},{"description":"Ixazomib 2.0 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months, Participants must also be refractory to their most recent therapy as evidenced by PD while on therapy or within 60 days after their last dose of therapy (Up to 1621 days).","id":"OG007","title":"Relapsed and Refractory Expansion Cohort: Ixazomib 2.0 mg/m^2"},{"description":"Ixazomib 2.0 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants with relapsed or refractory disease after \\>=1 prior therapy but have relapsed after previous Velcade exposure and were not treated with any other proteasome inhibitors (Up to 1573 days).","id":"OG008","title":"Velcade-Relapsed (VR) Expansion Cohort: Ixazomib 2.0 mg/m^2"},{"description":"Ixazomib 2.0 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determine the participant would benefit from therapy beyond 12 months. Participants with relapsed or refractory disease after \\>=1 prior therapy which must include thalidomide (or lenalidomide) and corticosteroid, but who never received a proteasome inhibitor.","id":"OG009","title":"Proteasome Inhibitor-Naive Expansion Cohort: Ixazomib 2 mg/m^2"},{"description":"Ixazomib 2.0 mg/m\\^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants who previously received carfilzomib and had relapsed or refractory disease (Up to 123 days).","id":"OG010","title":"Carfilzomib Expansion Cohort: Ixazomib 2.0 mg/m^2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population included all participants who received at least 1 dose of ixazomib.","reportingStatus":"POSTED","timeFrame":"From first dose of the study drug through 30 days after the last dose of study drug or start of subsequent antineoplastic therapy (Up to 81.1 months)","title":"Number of Participants With a TEAE of Peripheral Neuropathy","type":"PRIMARY","unitOfMeasure":"Participants"}